HUBUNGAN KOMORBIDITAS DAN PERILAKU TERHADAP TITER ANTIBODI DAN TERPAPAR COVID-19 PASCA VAKSIN ASTRAZENECA DOSIS LENGKAP DI UTA 45 JAKARTA
DOI:
https://doi.org/10.36387/jiis.v9i2.2028Keywords:
AstraZeneca vaccine, COVID-19, Antibody titers, Physical activity, Comorbidities, Smoking, Alcohol consumptionAbstract
AstraZeneca vaccine has become one of the efforts to overcome the COVID-19 pandemic. This study aims to determine the relationship between the AstraZeneca vaccine and antibody titers and its association with exposure to COVID-19 infection. This study used a retrospective and prospective cohort design with convenience sampling. A total of 102 respondents who had received a complete dose of the AstraZeneca vaccine and were willing to be followed up for 18 months were involved in this study. Sociodemographic data, comorbidity history, lifestyle, and antibody titers were measured at two times: before the first dose and after the second dose of vaccinations. This study found that there was no significant relationship between comorbidities and respondent behavior (smoking and alcohol consumption) with COVID-19 antibody titers. Physical activity (exercise) showed a positive relationship with COVID-19 antibody titers. Respondents who exercised regularly had higher antibody titers than those who did not. There was a positive relationship between comorbidities, smoking, and alcohol consumption with the risk of exposure to COVID-19 infection after vaccination. This study found that physical activity (exercise) can increase COVID-19 antibody titers and provide protection against COVID-19 infection after vaccination.
References
Ahmed, R., Lanier, J. G., & Pamer, E. (2002). Immunological Memory and Infection, dalam Kaufman, E ., Sher, A. and Ahmed, R.,. Imunologi Of Infection Disease, Asm Press, Washington D.C.
Barni, L., Carrasco-Vega, E., Olivieri, M., Galán-Mercant, A., Guiducci, S., Picariello, F., & González-Sánchez, M. (2023). Does Physical Exercise Enhance the Immune Response after Vaccination? A Systematic Review for Clinical Indications of COVID-19 Vaccine. International Journal of Environmental Research and Public Health, 20(6), 5183. https://doi.org/10.3390/ijerph20065183
Changeux, J.-P., Amoura, Z., Rey, F. A., & Miyara, M. (2020). A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. Comptes Rendus Biologies, 343(1), 33–39. https://doi.org/10.5802/crbiol.8
Chattopadhyay, S., Malayil, L., Kaukab, S., Merenstein, Z., & Sapkota, A. R. (2023). The predisposition of smokers to COVID-19 infection: A mini-review of global perspectives. Heliyon, 9(7), e17783. https://doi.org/10.1016/j.heliyon.2023.e17783
Collie, S., Saggers, R. T., Bandini, R., Steenkamp, L., Champion, J., Gray, G., Bekker, L.-G., Goga, A., Garrett, N., & Patricios, J. (2023). Association between regular physical activity and the protective effect of vaccination against SARS-CoV-2 in a South African case–control study. British Journal of Sports Medicine, 57(4), 205–211. https://doi.org/10.1136/bjsports-2022-105734
Dai, X., Tan, L., Ren, L., Shao, Y., Tao, W., & Wang, Y. (2022). COVID-19 Risk Appears to Vary Across Different Alcoholic Beverages. Frontiers in Nutrition, 8. https://doi.org/10.3389/fnut.2021.772700
Ferrara, P., Ponticelli, D., Agüero, F., Caci, G., Vitale, A., Borrelli, M., Schiavone, B., Antonazzo, I. C., Mantovani, L. G., Tomaselli, V., & Polosa, R. (2022). Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies. Public Health, 203, 97–99. https://doi.org/10.1016/j.puhe.2021.12.013
Hallam, J., Jones, T., Alley, J., & Kohut, M. L. (2022). Exercise after influenza or COVID-19 vaccination increases serum antibody without an increase in side effects. Brain, Behavior, and Immunity, 102, 1–10. https://doi.org/10.1016/j.bbi.2022.02.005
Huang, C.-F., Jang, T.-Y., Wu, P.-H., Kuo, M.-C., Yeh, M.-L., Wang, C.-W., Liang, P.-C., Wei, Y.-J., Hsu, P.-Y., Huang, C.-I., Hsieh, M.-Y., Lin, Y.-H., Hsiao, H.-H., Hsu, C.-M., Huang, C.-T., Lee, C.-Y., Chen, Y.-H., Chen, T.-C., Lin, K.-D., … Yu, M.-L. (2023). Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort. Virology Journal, 20, 112. https://doi.org/10.1186/s12985-023-02056-5
Kezia, V., & Ramatillah, D. L. (2022). Original Article INTENSIVE MONITROING OF SINOVAC VACCINE FOR SAFETY AND EFFICACY AMONG INDONESIAN POPULATION. 14(2), 44–48.
Khan, R., Albert, R., Awe, L., Four, R. D., Francois, T., Hinds, T., Kellman, A., Maharaj, K., Mahon, R., Pierre, C., Ramai, A., & Baksh, R. (2023). The knowledge, attitudes, and perceptions toward the Oxford AstraZeneca COVID-19 vaccine amongst Primary Health care workers in North-Central Trinidad. Frontiers in Public Health, 11. https://doi.org/10.3389/fpubh.2023.1094001
Knoll, M. D., & Wonodi, C. (2021). Oxford–AstraZeneca COVID-19 vaccine efficacy. The Lancet, 397(10269), 72–74. https://doi.org/10.1016/S0140-6736(20)32623-4
Kresno, B. S. (2010). Imunologi: Diagnosis dan Prosedur Laboratorium, EdisiV, hal 26, 30, 36, Badan Penerbit Fakultas Kedokteran Universitas Indonesia, Jakarta. 2010.
Lսkаѕ, Ѕ., Ramatillah, D. L., Jusnita, N., Fаdhіlla, Ѕ., Aldi, Y., & Wahyuni, F. S. (2022). Relationship between knowledge and attitude towards COVID-19 prevention behaviour among west jakarta residents. Pharmacy Education, 22(2), 289–291. https://doi.org/10.46542/pe.2022.222.289291
Mona, N. (2020). Konsep isolasi dalam jaringan sosial untuk meminimalisasi efek contagious (Kasus penyebaran virus corona di Indonesia). Jurnal Sosial Humaniora Terapan, 2(2), 117–125.
Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., Rosina, J., & Lesná, I. K. (2022). Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: A meta-analysis and meta-regression. BMC Medicine, 20(1), 461. https://doi.org/10.1186/s12916-022-02663-z
Raghotham, S., Balamuralidhara, V., & Karuna, K. (2019). Registration requirement and approval procedure of vaccines in Saudi Arabia. Research Journal of Pharmacy and Technology, 12(9), 4531–4538. https://doi.org/10.5958/0974-360X.2019.00780.7
Ramatillah, D. L., Alam, H. F., Hamid Ipadeola, M., Azhar, S., Sulaiman, S., Lukas, S., Jusnita, N., & Ramadhani, D. (2021). Public Knowledge about COVID-19 and Its Impact on the Psychic Condition of Indonesian Society. 48(8).
Riester, E., Findeisen, P., Hegel, J. K., Kabesch, M., Ambrosch, A., Rank, C. M., Pessl, F., Laengin, T., & Niederhauser, C. (2021). Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay. Journal of Virological Methods, 297, 114271. https://doi.org/10.1016/j.jviromet.2021.114271
Risk groups and COVID-19 | RIVM. (2023). RIVM Committed to Health and Sustainability. https://www.rivm.nl/en/coronavirus-covid-19/risk-groups
Roche Diagnostics GmbH. (2021). Elecsys Anti-SARS-CoV-2 S Protocol (09289267500; V2.0). Roche Diagnostics International Ltd.
Smits, P. D., Gratzl, S., Simonov, M., Nachimuthu, S. K., Goodwin Cartwright, B. M., Wang, M. D., Baker, C., Rodriguez, P., Bogiages, M., Althouse, B. M., & Stucky, N. L. (2023). Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine, 41(15), 2447–2455. https://doi.org/10.1016/j.vaccine.2023.02.038
Solopov, P. A. (2023). COVID-19 Vaccination and Alcohol Consumption: Justification of Risks. Pathogens, 12(2), 163. https://doi.org/10.3390/pathogens12020163
Tanriover, M. D., Doğanay, H. L., Akova, M., Güner, H. R., Azap, A., Akhan, S., Köse, Ş., Erdinç, F. Ş., Akalın, E. H., Tabak, Ö. F., Pullukçu, H., Batum, Ö., Şimşek Yavuz, S., Turhan, Ö., Yıldırmak, M. T., Köksal, İ., Taşova, Y., Korten, V., Yılmaz, G., … Aksu, K. (2021). Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet, 398(10296), 213–222. https://doi.org/10.1016/S0140-6736(21)01429-X
Utami, W., Rahmawati, R., Patonah, S., & Wahyudi, I. (2022). Adverse Events Following Immunization (AEFI) of COVID-19 vaccines and their association with comorbidities in health personnel and public servants in Indonesia. Public Health of Indonesia, 8(2), 39–45. https://doi.org/10.36685/phi.v8i2.587
Whitaker, H. J., Tsang, R. S. M., Byford, R., Andrews, N. J., Sherlock, J., Sebastian Pillai, P., Williams, J., Button, E., Campbell, H., Sinnathamby, M., Victor, W., Anand, S., Linley, E., Hewson, J., DArchangelo, S., Otter, A. D., Ellis, J., Hobbs, R. F. D., Howsam, G., … Lopez Bernal, J. (2022). Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. Journal of Infection, 84(5), 675–683. https://doi.org/10.1016/j.jinf.2021.12.044
WHO. (2021). Interim recommendations for use of the ChAdOx1-S [ recombinant ] vaccine against COVID-19. World Health Organization, 19(January), 1–12.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Jurnal Ilmiah Ibnu Sina
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
